Development of a novel imaging modality for adoptive cell therapy

摘要： 最近，一种新的癌症治疗方法显示出很高的前景，称为过继细胞治疗。这 这种方法涉及用免疫细胞如T细胞或自然杀伤（NK）细胞治疗患者，而不是用免疫细胞治疗患者。 药物治疗虽然一些细胞疗法对至少一部分癌症表现出很高的前景，但主要的治疗方法是细胞疗法。 该领域发展的技术挑战是缺乏对这些细胞驻留在哪里的知识 一旦被注入体内。虽然容易监测血液中输注的药物的存在， 免疫细胞，没有令人满意的方法来监测运输到组织中的细胞（例如，结肠肿瘤）。在 根据这项提议，我们将开发一种新的方法，使用纳米气泡（NB）标记免疫细胞。这些标签 然后可以使用超声波非侵入性地监测细胞。由于NB是FDA的组成部分， 我们预计这种方法不仅安全，而且可以快速转化为人类 试验.希望这项工作将导致新的技术，使我们能够监测贩运人口的情况。 免疫细胞疗法，以便我们可以最佳地选择哪些患者/肿瘤类型将最受益于免疫细胞疗法， 给予细胞治疗产品。

Abstract: Recently a new therapeutic approach for cancer has exhibited high promise termed adoptive cell therapy. This approach involves treating patients with immune cells such as T cells or Natural Killer (NK) cells instead of drug therapy. While some cell therapies have exhibited high promise for at least a subset of cancers, a major technological challenge in the development of this field is the lack of knowledge of where these cells reside in the body once they are infused. While it is readily easy to monitor the blood for the presence of the infused immune cells, there is no satisfactory method to monitor the cells that traffic into tissue (ex. colon tumors). In this proposal, we will develop a novel method to label immune cells using nanobubbles (NBs). These labelled cells then can be monitored non-invasively using an ultrasound. As NBs are a component of an already FDA approved product, we anticipate this approach will not only be safe but can be translated quickly to human testing. It is hoped that this work will lead to new technology that will enable us to monitor the trafficking of immune cell therapies so that we can optimally select which patients/tumor types would most benefit from a given cell therapy product.